#125 Nicotinamide Adenine Dinucleotide (NAD) Clinical Updates

1.5 CE Total | 1.5 Pharm

Now with AMA PRA Cat-1 CME (ACCME) Credit!

This course will have AMA PRA Cat-1 CME (ACCME) credit for one (1) year after being recorded on March 18th, 2025. Renewal will be done through AANP.

Abstract:

NAD Pharmacology has become more commonly included in therapeutic interventions in the past decade. Direct (parenteral) applications via IV and IM routes have seen increased use and oral “NAD Support” protocols via niacinamide, NR, NMN and others have also seen great interest. This CME is designed to update the clinician in all the relevant areas around the augmentation of NAD function, safety issues, and uses of oral and parenteral agents in doing so.

Learning Objective:

• Describe the biochemistry of NAD in the human
• Describe the pharmacology of NAD and precursors
  • Niacinamide
  • Nicotinamide Riboside (NR)
  • Nicotinamide Adenine Dinucleotide (NADH)
  • Nicotinamide Mononucleotide (NMN)
• Describe the common oral NAD supports and their limitations
  • Niacinamide
  • Nicotinamide Riboside (NR)
  • Nicotinamide Adenine Dinucleotide (NADH)
  • Nicotinamide Mononucleotide (NMN)
• Describe the use of parenteral (IV /IM) NAD drugs
  • Niacinamide
  • Nicotinamide Riboside (NR)
  • NAD+
  • Nicotinamide Adenine Dinucleotide (NADH) – historical information
• Discuss safety aspects of all mentioned interventions

Outline:

• NAD Function: Biochemistry and Pharmacology
• NAD Oral Support Pharmacology
• NAD Parenteral Support Pharmacology

All certificates will be given through the ACCME link for one (1) year after being recorded. CDA is not responsible for certificates.